Dinakar Chitra, Reddy Mamta
Section of Asthma, Allergy, and Immunology, Children's Mercy Hospital, Kansas City, Missouri 64108-4968, USA.
Ann Allergy Asthma Immunol. 2004 Jan;92(1):7-16; quiz 16-7, 79. doi: 10.1016/S1081-1206(10)61704-8.
To review the available literature on methods of preventing and minimizing exacerbations and to target problems for improvement.
PubMed and Cochrane Review searches of the English-language literature using the following key yellow zone terms: asthma exacerbation, self-management plans, inhaled corticosteroids, and acute management of asthma exacerbations.
Articles relevant to our yellow zone intervention inquiry.
The National Institutes of Health (NIH) guidelines advocate that physicians give patients written action plans with instructions on managing home (yellow zone) exacerbations. However, the criteria used to identify the yellow zone are ambiguous and often confusing to patients and physicians. In addition, apart from a passing mention that doubling doses of inhaled corticosteroids may be an option in asthma step-up care, the guidelines contain no recommendations for yellow zone treatment strategies. This deficiency is directly related to the paucity of organized evidence on the efficacy of the various pharmacological interventions that can be used during an exacerbation.
Translating the NIH guidelines into realistic clinical practice requires a clearer and more patient-friendly definition of the yellow zone, and this improved definition will facilitate the prescription of effective interventions in the management of yellow zone exacerbations.
回顾关于预防和减少哮喘加重发作方法的现有文献,并确定有待改进的问题。
通过PubMed和考克兰系统评价数据库检索英文文献,检索词为以下关键“黄区”术语:哮喘加重发作、自我管理计划、吸入性糖皮质激素以及哮喘加重发作的急性处理。
与我们的“黄区”干预调查相关的文章。
美国国立卫生研究院(NIH)指南提倡医生为患者提供书面行动计划,其中包含关于处理家庭(黄区)哮喘加重发作的指导说明。然而,用于确定黄区的标准并不明确,常常让患者和医生感到困惑。此外,除了在哮喘升级治疗中顺便提及加倍吸入性糖皮质激素剂量可能是一种选择外,该指南未对黄区治疗策略提出任何建议。这一缺陷与在哮喘加重发作期间可使用的各种药物干预措施疗效的系统性证据匮乏直接相关。
要将NIH指南转化为切实可行的临床实践,需要对黄区进行更清晰、更便于患者理解的定义,而这一改进后的定义将有助于在处理黄区哮喘加重发作时开具有效的干预措施处方。